Cardiovascular Gene Therapy: Angiogenesis and Beyond

American Journal of the Medical Sciences

Volumn 327, Issue 3, 2004, Pages 139-148

  Bekeredjian, Raffi ^a   Shohet, Ralph V ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Cardiovascular gene therapy

Indexed keywords

ADENOSINE DEAMINASE; ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENYLATE CYCLASE; ALANINE AMINOTRANSFERASE; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BETA ADRENERGIC RECEPTOR; CATECHOLAMINE; CYTOKINE; DNA; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR; HELICASE; HYPOXIA INDUCIBLE FACTOR 1; IMMUNOGLOBULIN; KALLIKREIN; KININ; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PLACEBO; PLASMID DNA; PROTEIN; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RYANODINE RECEPTOR; SCATTER FACTOR; UNINDEXED DRUG; VASCULOTROPIN; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANGIOGENESIS; APOPTOSIS; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONFERENCE PAPER; EDEMA; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; HEART ARRHYTHMIA; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; INTRACORONARY INFUSION; MORBIDITY; MORTALITY; NONHUMAN; RETROVIRUS; TRANSGENE;

EID: 1542343939     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200403000-00005     Document Type: Conference Paper

References (85)

1. Isner JM. Myocardial gene therapy. Nature 2002;415:234-9.
2. Yla-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet 2000;355:213-22.
3. Khurana R, Simons M. Insights from angiogenesis trials using fibroblast growth factor for advanced arteriosclerotic disease. Trends Cardiovasc Med 2003;13:116-22.
4. Grossman M, Raper SE, Kozarsky K, et al. Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 1994;6:335-41.
5. Grossman M, Rader DJ, Muller DW, et al. A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995;1:1148-54.
6. Thalhamer J, Leitner W, Hammerl P, et al. Designing immune responses with genetic immunization and immunostimulatory DNA sequences. Endocr Regul 2001;35:143-66.
7. Fomsgaard A. Genetic immunization-"the biological equivalent of cold fusion"? Ugeskr Laeger 1995;157:4932-6.
8. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992;356:152-4.
9. Quarck R, Holvoet P. Restenosis and gene therapy. Expert Opin Biol Ther 2001;1:79-91.
10. Santiago FS, Khachigian LM. Nucleic acid based strategies as potential therapeutic tools: mechanistic considerations and implications to restenosis. J Mol Med 2001;79:695-706.
11. Shuey DJ, McCallus DE, Giordano T. RNAi: gene-silencing in therapeutic intervention. Drug Discov Today 2002;7:1040-6.
12. Havenga MJ, Lemckert AA, Grimbergen JM, et al. Improved adenovirus vectors for infection of cardiovascular tissues. J Virol 2001;75:3335-42.
13. Wickham TJ. Targeting adenovirus. Gene Ther 2000;7:110-14.
14. Young LS, Mautner V. The promise and potential hazards of adenovirus gene therapy. Gut 2001;48:733-6.
15. Qian HS, Channon K, Neplioueva V, et al. Improved adenoviral vector for vascular gene therapy: beneficial effects on vascular function and inflammation. Circ Res 2001;88:911-7.
16. Symes JF, Losordo DW, Vale PR, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999;68:830-6; discussion 836-7.
17. Cable DG, Caccitolo JA, Caplice N, et al. The role of gene therapy for intimal hyperplasia of bypass grafts. Circulation 1999;100(19 Suppl):II392-6.
18. Mangi AA, Dzau VJ. Gene therapy for human bypass grafts. Ann Med 2001;33:153-5.
19. Chiu-Pinheiro CK, O'Brien T, Katusic ZS, et al. Gene transfer to coronary artery bypass conduits. Ann Thorac Surg 2002;74:1161-6; discussion 1166.
20. White SJ, Newby AC. Gene therapy for all aspects of vein-graft disease. J Card Surg 2002;17:549-55.
21. Lazarous DF, Shou M, Stiber JA, et al. Adenoviral-mediated gene transfer induces sustained pericardial VEGF expression in dogs: effect on myocardial angiogenesis. Cardiovasc Res 1999;44:294-302.
22. Varenne O, Gerard RD, Sinnaeve P, et al. Percutaneous adenoviral gene transfer into porcine coronary arteries: is catheter-based gene delivery adapted to coronary circulation? Hum Gene Ther 1999;10:1105-15.
23. Zsigmond E, Kobayashi K, Tzung KW, et al. Adenovirus-mediated gene transfer of human lipoprotein lipase ameliorates the hyperlipidemias associated with apolipoprotein E and LDL receptor deficiencies in mice. Hum Gene Ther 1997;8:1921-33.
24. Applebaum-Bowden D, Kobayashi J, Kashyap VS, et al. Hepatic lipase gene therapy in hepatic lipase-deficient mice. Adenovirus-mediated replacement of a lipolytic enzyme to the vascular endothelium. J Clin Invest 1996;97:799-805.
25. Khurana R, Martin JF, Zachary I. Gene therapy for cardiovascular disease: a case for cautious optimism. Hypertension 2001;38:1210-6.
26. Budts W, Pokreisz P, Nong Z, et al. Aerosol gene transfer with inducible nitric oxide synthase reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling in rats. Circulation 2000;102:2880-5.
27. Gunnett CA, Heistad DD. The future of gene therapy for stroke. Curr Hypertens Rep 2001;3:36-40.
28. Mann MJ, Whittemore AD, Donaldson MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 1999;354:1493-8.
29. Simons M, Edelman ER, DeKeyser JL, et al. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992;359:67-70.
30. Chang MW, Barr E, Seltzer J, et al. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 1995;267:518-22.
31. Isner JM, Pieczek A, Schainfeld R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996;348:370-4.
32. Ornitz DM, Itoh N. Fibroblast growth factors. Genome Biol 2001;2:REVIEWS3005.
33. Powers CJ, McLeskey SW, Wellstein A. Fibroblast growth factors, their receptors and signaling. Endocr Relat Cancer 2000;7:165-97.
34. Zhou M, Sutliff RL, Paul RJ, et al. Fibroblast growth factor 2 control of vascular tone. Nat Med 1998;4:201-7.
35. Scholz D, Cai WJ, Schaper W. Arteriogenesis, a new concept of vascular adaptation in occlusive disease. Angiogenesis 2001;4:247-57.
36. Post MJ, Laham R, Sellke FW, et al. Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc Res 2001;49:522-31.
37. Schumacher B, Pecher P, von Specht BU, et al. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 1998;97:645-50.
38. Ruel M, Laham RJ, Parker JA, et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg 2002;124:28-34.
39. Laham RJ, Chronos NA, Pike M, et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a phase I open-label dose escalation study. J Am Coll Cardiol 2000;36:2132-9.
40. Simons M, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-93.
41. Giordano FJ, Ping P, McKirnan MD, et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996;2:534-9.
42. Wright MJ, Wightman LM, Lilley C, et al. In vivo myocardial gene transfer: optimization, evaluation and direct comparison of gene transfer vectors. Basic Res Cardiol 2001;96:227-36.
43. Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-7.
44. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989;161:851-8.
45. Connolly DT, Heuvelman DM, Nelson R, et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989;84:1470-8.
46. Keck PJ, Hauser SD, Krivi G, et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989;246:1309-12.
47. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
48. Takeshita S, Pu LQ, Stein LA, et al. Intramuscular ad-ministration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 1994;90:II228-34.
49. Hariawala MD, Horowitz JR, Esakof D, et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 1996;63:77-82.
50. Lopez JJ, Laham RJ, Carrozza JP, et al. Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. Am J Physiol 1997;273:H1317-23.
51. Sato K, Wu T, Laham RJ, et al. Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. J Am Coll Cardiol 2001;37:616-23.
52. Baumgartner I, Pieczek A, Manor O, et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998;97:1114-23.
53. Rosengart TK, Lee LY, Patel SR, et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999;100:468-74.
54. Henry TD, Annex BH, McKendall GR, et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003;107:1359-65.
55. Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002;105:2012-8.
56. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Concensus (TASC). J Vasc Surg 2000;31(1 Pt 2):S1-S296.
57. Springer ML, Chen AS, Kraft PE, et al. VEGF gene delivery to muscle: potential role for vasculogenesis in adults. Mol Cell 1998;2:549-58.
58. Kloner RA, Dow J, Chung G, et al. Intramyocardial injection of DNA encoding vascular endothelial growth factor in a myocardial infarction model. J Thromb Thrombolysis 2000;10:285-9.
59. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
60. Isner JM, Vale PR, Symes JF, et al. Assessment of risks associated with cardiovascular gene therapy in human subjects. Circ Res 2001;89:389-400.
61. Frank RN, Amin RH, Eliott D, et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996;122:393-403.
62. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
63. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994;118:445-50.
64. Okamoto N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 1997;151:281-91.
65. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983-5.
66. Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999;286:2511-4.
67. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460-3.
68. Baumgartner I, Rauh G, Pieczek A, et al. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 2000;132:880-4.
69. Fuchs S, Baffour R, Vodovotz Y, et al. Laser myocardial revascularization modulates expression of angiogenic, neuronal, and inflammatory cytokines in a porcine model of chronic myocardial ischemia. J Card Surg 2002;17:413-24.
70. Hedman M, Hartikainen J, Syvanne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia. Phase II Results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003;107:2677-83.
71. Pola R, Ling LE, Silver M, et al. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat Med 2001;7:706-11.
72. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A 1998;95:7987-92.
73. Hajjar RJ, del Monte F, Matsui T, et al. Prospects for gene therapy for heart failure. Circ Res 2000;86:616-21.
74. MacNeill BD, Hayase M, Hajjar RJ. Targeting signaling pathways in heart failure by gene transfer. Curr Atheroscler Rep 2003;5:178-85.
75. Miyamoto MI, del Monte F, Schmidt U, et al. Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc Natl Acad Sci U S A 2000;97:793-8.
76. Hoshijima M, Ikeda Y, Iwanaga Y, et al. Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat Med 2002;8:864-71.
77. Rockman HA, Chien KR, Choi DJ, et al. Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc Natl Acad Sci U S A 1998;95:7000-5.
78. Weig HJ, Laugwitz KL, Moretti A, et al. Enhanced cardiac contractility after gene transfer of V2 vasopressin receptors in vivo by ultrasound-guided injection or transcoronary delivery. Circulation 2000;101:1578-85.
79. White DC, Hata JA, Shah AS, et al. Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. Proc Natl Acad Sci U S A 2000;97:5428-33.
80. Brocheriou V, Hagege AA, Oubenaissa A, et al. Cardiac functional improvement by a human Bcl-2 transgene in a mouse model of ischemia/reperfusion injury. J Gene Med 2000;2:326-33.
81. Fujio Y, Nguyen T, Wencker D, et al. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000;101:660-7.
82. Agata J, Chao L, Chao J. Kallikrein gene delivery improves cardiac reserve and attenuates remodeling after myocardial infarction. Hypertension 2002;40:653-9.
83. Li Y, Takemura G, Kosai K, et al. Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation 2003;107:2499-506.
84. Nuss HB, Marban E, Johns DC. Overexpression of a human potassium channel suppresses cardiac hyperexcitability in rabbit ventricular myocytes. J Clin Invest 1999;103:889-96.
85. Miake J, Marban E, Nuss HB. Biological pacemaker created by gene transfer. Nature 2002;419:132-3.